IL17A and psoriasis: Even the relatively low-potency DXM group exhibited a similar ability to inhibit the protein expression of the IL-23/IL-17/TNF-α axis in psoriasis-like skin when compared with high-potency steroids such as ESP and CLO (Figure 3F–J).